Keybank National Association OH lowered its holdings in shares of Celgene Co. (NASDAQ:CELG) by 1.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 822,619 shares of the biopharmaceutical company’s stock after selling 9,252 shares during the period. Celgene accounts for 0.7% of Keybank National Association OH’s investment portfolio, making the stock its 29th largest holding. Keybank National Association OH owned 0.11% of Celgene worth $119,954,000 as of its most recent SEC filing.
A number of other large investors have also modified their holdings of CELG. PNC Financial Services Group Inc. increased its holdings in Celgene by 13.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 787,046 shares of the biopharmaceutical company’s stock valued at $97,934,000 after acquiring an additional 91,679 shares in the last quarter. Legal & General Group Plc boosted its stake in shares of Celgene by 4.3% during the 1st quarter. Legal & General Group Plc now owns 3,587,623 shares of the biopharmaceutical company’s stock worth $446,406,000 after purchasing an additional 147,263 shares during the last quarter. State Street Corp boosted its stake in shares of Celgene by 2.3% during the 1st quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company’s stock worth $4,040,668,000 after purchasing an additional 723,844 shares during the last quarter. Wedgewood Partners Inc. acquired a new stake in shares of Celgene during the 1st quarter worth about $23,890,000. Finally, Cypress Capital Group boosted its stake in shares of Celgene by 4.8% during the 1st quarter. Cypress Capital Group now owns 35,292 shares of the biopharmaceutical company’s stock worth $4,392,000 after purchasing an additional 1,602 shares during the last quarter. Hedge funds and other institutional investors own 79.74% of the company’s stock.
CELG has been the topic of several research analyst reports. Royal Bank of Canada reissued a “buy” rating and issued a $173.00 target price on shares of Celgene in a research report on Thursday, October 5th. Morgan Stanley cut shares of Celgene from an “equal weight” rating to an “underweight” rating and set a $120.00 price target on the stock. in a research report on Thursday, October 5th. Robert W. Baird reaffirmed a “buy” rating and set a $162.00 price target on shares of Celgene in a research report on Thursday, September 21st. Cantor Fitzgerald reaffirmed a “buy” rating and set a $162.00 price target on shares of Celgene in a research report on Tuesday, September 26th. Finally, Jefferies Group reiterated a “buy” rating and set a $160.00 price objective on shares of Celgene in a research note on Friday, September 15th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and nineteen have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $131.18.
Shares of Celgene Co. (NASDAQ:CELG) traded up $1.42 on Friday, hitting $106.00. The stock had a trading volume of 8,748,713 shares, compared to its average volume of 6,330,000. The firm has a market cap of $83,460.00, a P/E ratio of 25.00, a price-to-earnings-growth ratio of 0.67 and a beta of 1.77. Celgene Co. has a one year low of $94.55 and a one year high of $147.17. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31.
Celgene (NASDAQ:CELG) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.87 by $0.04. The business had revenue of $3.29 billion during the quarter, compared to analysts’ expectations of $3.42 billion. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.58 EPS. equities analysts predict that Celgene Co. will post 6.69 earnings per share for the current year.
WARNING: This article was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/01/13/keybank-national-association-oh-has-119-95-million-holdings-in-celgene-co-celg.html.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.